Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Nascent Biotech Inc (OP: NBIO )

0.0450 +0.0020 (+4.65%)
Streaming Delayed Price Updated: 2:17 PM EDT, Aug 15, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 350,501
Open 0.0440
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 0.0430
Today's Range 0.0430 - 0.0455
52wk Range 0.0360 - 0.2800
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Nascent Biotech Presents at the July Emerging Growth Conference
Via ACCESSWIRE
Nascent Prepares for Pivotal Phase II Research with Fresh Manufacturing Run
Via ACCESSWIRE

Performance

YTD
-72.14%
-72.14%
1 Month
-33.92%
-33.92%
3 Month
-53.89%
-53.89%
6 Month
-58.72%
-58.72%
1 Year
-30.77%
-30.77%

More News

Read More
Nascent Collaborates With Hypospray Pharma on Proprietary Transdermal Delivery System
Via ACCESSWIRE
Nascent Biotech and Manhattan BioSolutions Collaborate to Explore Pritumumab Antibody-Drug Conjugates
Via ACCESSWIRE
Nascent Biotech Receives an Analyst Opinion Suggesting that of the Company is Significantly Under Valued
Via ACCESSWIRE
Nascent Biotech Completes Payment of Variable Convertible Note in Full to Eliminate Dilution Risk
Via ACCESSWIRE
Nascent Biotech Granted Japanese Patent for Crossing Blood-Brain Barrier
Via ACCESSWIRE
Nascent Biotech to Begin Phase II Clinical Trials for Brain Cancer
Via ACCESSWIRE
Nascent Biotech Phase I Clinical Data Presented at the American Society of Clinical Oncology Annual Meeting
Via ACCESSWIRE
Nascent Biotech Regains Worldwide Rights for Pritumumab
Via ACCESSWIRE
Nascent Biotech to Present Phase I Clinical Data at American Society of Clinical Oncology Annual Meeting
Via ACCESSWIRE
Nascent Submits Phase 2 Clinical Research Protocol to FDA for Review and Approval
Via ACCESSWIRE
Nascent Announces the Completion of Its Phase1 Clinical Trials
Via ACCESSWIRE
Nascent Completes Dosing Requirement in Final Cohort of Phase I Clinical Trial
Via ACCESSWIRE
Nascent Enrolls Final Patient Cohort in Phase I Brain Cancer Trial
Via ACCESSWIRE
Nascent Biotech Announces Appointment of Dr. Ivan Babic to Scientific Advisory Board
Via ACCESSWIRE
Nascent Biotech Receives Notice of the Issuance of US Patent No.11,494,394
Via ACCESSWIRE
Nascent Begins Enrollment of Final Patient Cohort to Complete Phase One Clinical Research
Via ACCESSWIRE
Nascent Biotech Completes Fourth Cohort in Phase 1 Human Trial for Primary and Metastatic Brain Cancer
Via ACCESSWIRE
Nascent Biotech Receives Notice of Allowance from USPTO for Issuance of Additional Patent
Via ACCESSWIRE
Nascent Biotech Receives Notice of Allowance from USPTO for Issuance of Additional Patent
From Nascent Biotech Inc.
Via AccessWire
Topics Intellectual Property
Exposures Intellectual Property
Nascent Biotech Completes Third Cohort in Phase 1 Human Trial for Primary and Metastatic Brain Cancer
From Nascent Biotech Inc.
Via AccessWire
Nascent Biotech's CEO Sean Carrick Featured in In-Depth Interview with Proactive Investors
From Nascent Biotech Inc.
Via AccessWire
Nascent Biotech and BioTools Partner in the Fight Against Cancer Using ROA to Define the Higher Order Structure of PTB, a Unique Monoclonal Antibody
From Nascent Biotech Inc.
Via AccessWire
The Laurel Amtower Cancer Institute and Neuro-Oncology Center at Sharp HealthCare to Join Innovative Antibody Brain Cancer Drug Trial
From Nascent Biotech Inc.
Via AccessWire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.